Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Biomark Diagnostics Inc. (C:BUX)

Business Focus: Diagnostic & Testing Substances Manufacturers

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 130 - 3851 Shell Rd
Tel: N/A
IR: See website
Key People
Business Overview
Biomark Diagnostics Inc. is an analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting investigational new drug (IND) and new drug application (NDA)-enabling studies. The Company is engaged in the cancer diagnostics using metabolites. The Company's metabolomics-based diagnostic assay allows cancer detection. The assay consists of screening for the acetylated form of a drug (Amantadine) given to patients prior to measurement through liquid chromatography mass spectrometry (LC MS) in body fluids. This acetylation is performed by the enzyme, spermine/spermidine N-acetyl transferase (SSAT). SSAT is observed in various cancers, including lung, breast, prostate, melanoma and gastrointestinal (GI) cancers. The analysis of SSAT messenger ribonucleic acid (mRNA) levels in tissue samples allows determination of cancer type.
Financial Overview
For the fiscal year ended 31 March 2021, BioMarkDiagnostics Inc revenues decreased from C$263K to C$0K. Netloss decreased 10% to C$1.1M. Revenues reflect a decreasein demand for the Company's products and services due tounfavorable market conditions. Lower net loss reflectsShare-based compensation decrease of 54% to C$395K(expense), Travel decrease of 67% to C$7K (expense), Officeand miscellaneous decrease of 43% to C$20K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $15.62M as of Mar 31, 2021
Annual revenue (TTM): $0.00M as of Mar 31, 2021
EBITDA (TTM): -$1.07M as of Mar 31, 2021
Net annual income (TTM): -$1.09M as of Mar 31, 2021
Free cash flow (TTM): -$0.46M as of Mar 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 77,974,229 as of Apr 19, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization